What is the Parkinson Study Group (PSG)?

The Parkinson Study Group (PSG) is a non-profit group of physicians and other health care providers from medical centers in the United States, Canada and Puerto Rico experienced in the care of Parkinson patients and dedicated to clinical research of Parkinson disease. The PSG was formed in 1986, prompted by the recognition that clinical research in Parkinson disease (PD) required the participation of large numbers of research patients (subjects) under the cooperative care of skilled and experienced research physicians.

The PSG aims to advance knowledge about the cause(s), disease progression and treatment of PD and related disorders. The PSG is committed to:

  • open communication within the scientific community;
  • ensuring research is peer reviewed by other health care providers prior to publication and that all research results are available to the public;
  • revealing potential conflicts of interest of the group and each PSG member and;
  • democratic governance of its organizations and activities.

PSG Mentorship Program

PSG Visiting Mentorship Program

The PSG Visiting Mentorship Program is funded by a grant from Sunovion Pharmaceuticals. The goal of this program is to promote the continued development of newly trained movement disorders clinician-researchers into world-class investigators. This initiative focuses on the mentorship of young investigators committed to clinical research in the Parkinson’s arena by seasoned, established clinical investigators. While there are several courses and conferences that a young investigator can participate in, there is no substitute for a personal mentor-mentee relationship, where the mentor can review the mentee’s proposed initiative(s), and meet with the mentee’s team, local setup, and provide in-person sage advice.

Available funds: PSG will award up to four awards totaling $7,450, including $5,000 for mentor honorarium and $2,450 for travel, meals, and incidentals related to mentoring.

The Project:

  • VMP funding announcement coming spring 2022
 

AWARDED INVESTIGATORS

2019-2020
Gregory Pontone, MS, MHS and Jared Hinkle, Johns Hopkins University, were awarded $12,500 to study “Phenotypic and Prognostic Significance of Panic Disorder in PD”.

2018-2019
Peter LeWitt, MD, Henry Ford W Bloomfield Hospital, W. Bloomfield, MI was awarded $30,000 to study “Polyamine Biomarkers of PD Progression”.

2017-2018
Ruth Schneider, MD, University of Rochester Medical Center, Rochester, NY, was awarded $31,653 to study “Early vs Delayed Initiation of Dopaminergic Treatment in PD”.

2015-2016
Anne-Marie Wills, MD, MPH, Massachusetts General Hospital, Charlestown, MA was awarded $22,950 to study “Body Mass Index and PD Survival”.

Click on any red project title to download the abstract.

October 2014
Rachel Biemiller, MD, University of Rochester Medical Center, Rochester, NY was awarded $25,000 to study “PD phenotype and response to dopaminergic therapy: a secondary analysis of the CALM-PD trial”.

December 2013
Connie Marras, MD, PhD and Genetics/Environmental Risk Working Group was awarded $11,000 to study “The PSG PD Risk Factor Data Inventory: Developing a resource to facilitate data-mining studies”.

Ivan Bodis Wollner, MD, DSc, Professor of Neurology and Ophthalmology, Director, Parkinson Disease Clinic, Kings County Hospital Center and Attending Neurologist, SUNY Health Science Center at Brooklyn, New York, was awarded $14,000 to study “The relationship between levodopa therapy and inner retinal layer thickness by OCT in patients with PD”.

December 2012
Elizabeth L. Stegemoller, PhD, Postdoctoral Fellow, Neurobiomechanics Laboratory, Department of Applied Physiology and Kinesiology, University of Florida, Center for Movement Disorders and Neurorestoration, Gainesville, Florida was awarded a $24,995.18 grant supported by the Parkinson’s Disease Foundation for her planning project entitled “Effects of Singing on Speech and Swallowing in Patients with Parkinson’s Disease”.

February 2012 Ivan Bodis-Wollner, MD, DSc, Professor of Neurology and Ophthalmology, Director, Parkinson Disease Clinic, Kings County Hospital Center and Attending Neurologist, State University of New York – Health Science Center at Brooklyn, New York, was awarded a $9,930 grant supported by the Parkinson’s Disease Foundation for his planning project entitled “Synucleinopathy of the retina in Parkinson disease”.

Click on any red project title to download the abstract.

October 2011
Peter LeWitt, MD, Wayne State University, Director, Parkinson’s Disease and Movement Disorders Program, Michigan, was awarded a $12,559 grant from the PSG and Parkinson’s Disease Foundation for his datamining project entitled “COMT met genotype polymorphism and cognitive performance in PD with and without selegiline treatment”.

September 2010
Matthew Menza, MD, Professor, Psychiatry & Neurology, Robert Wood Johnson Medical School, New Jersey, was awarded a $9,200 grant from the PSG and Parkinson’s Disease Foundation for his datamining project entitled “An Exploration of the Association of Inflammatory Cytokines and the Non-Motor Symptoms of PD in Patients in DATATOP”.

February 2010
Un Jung Kang, MD, Professor of Neurology, University of Chicago Medical Center, was awarded a $7,600 grant from the PSG and Parkison’s Disease Foundation for his datamining project entitled “The role of motor learning in dopaminergic therapy of PD”.

October 2009
Xuemei Huang, MD, PhD, Associate Professor of Neurology, Penn State Hershey Medical Center, was awarded a $13,200 grant from the PSG and Parkinson’s Disease Foundation for her datamining project entitled “Serum cholesterol level as a predictor of progression in PD”. Dr. Huang will be working with Honglei Chen of NIEHS and co-investigator’s Alberto Ascherio of Harvard School of Public Health and Michael Schwarzschild or Harvard Medical School.

February 2009
Timothy J. Collier, PhD, Professor of Neurology, University of Cincinnati Medical Center, was awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for his datamining project entitled “Antidepressant Induced Delay of Motor Symptoms in PD (AIDS-PD)”. The co-investigator, Katrina Paumier, BS, is a PhD candidate under Dr. Collier’s direction. This project will be coordinated with the PSG Genetics and Environmental Working Group funded project on “Impact of commonly-prescribed medications on PD progression” led by Andrew Siderowf, MD, MSCE.

Click on any red project title to download the abstract.

October 2008
Robert A. Hauser, MD, Professor of Neurology, Pharmacology and Experimental Therapeutics at the University of South Florida, was awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for his datamining project entitled “Determination of Minimally Clinically Important Change in Early and Advanced Parkinson’s Disease”. Peggy Auinger, MS is co-PI on the project.

May 2008
Marian Evatt, MD, MS, Assistant Professor of Neurology at Emory University and Assistant Director of the Movement Disorders Program at Wesley Woods Hospital, Atlanta, GA, was awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for her datamining project entitled “Vitamin D Insufficiency: Prevalence and Clinical Correlates in the DATATOP Cohort”. Vin Tangpricha, MD, PhD and Mahlon R. Delong, MD serve as co-PIs on the project.

October 2007
Ergun Uc, MD, Associate Professor of Neurology at Carver College of Medicine, University of Iowa, was awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for his datamining project entitled “Weight loss in Parkinson’s disease”. This was a collective effort of the PSG Other Non-Motor Features of PD Working Group with Carlos Singer, MD, Jay Rao, MD, and David Oakes, PhD as co-investigators.

Connie Marras, MD, PhD, Assistant Professor at Toronto Western Hospital, University of Toronto Movement Disorders Centre, was awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for her planning project entitled “Environmental exposures modifying clinical expression of LRRK2-associated Parkinson’s disease”. Caroline Tanner, MD, PhD and Anthony Lang, MD serve as co-PIs on the project.

July 2007
Jing Zhang, MD, PhD, Associate Professor of Pathology, Shaw Endowed Professorship in Neuropathology Division of Neuropathology Harborview Medical Center, University of Washington School of Medicine, Seattle, WA, was awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for his datamining research proposal entitled “Using human cerebrospinal fluid samples collected in DATATOP study for biomarker discovery in patients with Parkinson’s disease”. This was a collective effort of the PSG Biomarkers Working Group. Un Jung Kang, MD will be an active participant and advisor on this project. Michael McDermott, PhD will provide statistical support.

June 2007
Michael Schwarzschild, MD, PhD, Associate Professor of Neurology, at Harvard Medical School, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital has been awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for his datamining project entitled “Predicting PD Progression Subtypes by CSF Urate Pathways”. Alberto Ascherio, MD, PhD serves as co-PI on the project.

February 2007
Ergun Uc, MD, Assistant Professor of Neurology, of the Divisions of Movement Disorders & Neuroergonomics, Department of Neurology, University of Iowa Hospitals & Clinic, was awarded a $25,000 grant from the PSG and Parkinson’s Disease Foundation for his datamining project entitled “Predictors and Course of Cognitive Decline and Depression Early in the Course of PD based on the DATATOP Cohort”.This was a collective effort of the PSG Cognitive/Psychiatric Working Group with John Growdon, Kelvin Chou, Karen Marder, Irene Litvan, Michel Panisset, Steve Anderson, and Peter Como all as co-investigators. Michael McDermott, PhD is the statistical co-PI.

Mentoring Committee

WHAT IS THE PSG MENTORING COMMITTEE (MC)?

The PSG Mentoring Committee (MC) has three main roles.

1. To solicit, review, and select candidates to receive the Parkinson’s Disease Foundation supported mentored clinical research award. This is a major award in support of a project that is a practical training ground for individuals to acquire new skills and expertise in clinical research.

1. To serve as a resource for individuals who need assistance in formulating and developing protocols to the point where they are ready for review by the Scientific Review Committee.

1. To develop and organize innovative programs to promote interest in Parkinson’s disease research, facilitate the development of mentorship relationships, and increase awareness of resources within the PSG that can provide opportunities for initiating research efforts.

The Mentoring Committee oversees the PSG Advisor Program. Implemented in 2009, the PSG Advisor Program helps new investigators find a local mentor or specific research funding sources for their research.

Download a PDF of the member list here.


Brad A. Racette, MD, Chair (2018-2021)
Washington University School of Medicine
Department of Neurology
660 South Euclid Avenue Campus Box 8111
St Louis, MO 63110
(314) 362-8548 Fax: (314) 747-8289
racetteb@neuro.wustl.edu
Assistant: Tracey Erdman – erdmant@neuro.wustl.edu

James Leverenz, MD, Co-Chair (2018-2021)
Director, Cleveland Lou Ruvo Center for Brain Health
Dr. Joseph Hahn Endowed Chair of Neurological Sciences
Cleveland Clinic
9500 Euclid Avenue, U10
Cleveland, OH 44195
(216) 636-4044
leverej@ccf.org
Assistant: Shelley Sekerak – sekeras2@ccf.org

Roy Alcalay, MD, MSc (2019-2022)
Columbia University
710 W. 168th Street
New York, NY 10032
rna2104@cumc.columbia.edu

John L. Goudreau, DO, PhD (2018-2021)
Director, Translational Neurobiology Research Unit Director, Movement Disorders Clinic Associate
Professor Department of Neurology Department of Pharmacology & Toxicology
B407 Clinical Center
Michigan State University
East Lansing, MI 48824
(517) 432-9277 Fax: (517)-432-9414
john.goudreau@ht.msu.edu
Assistant: Krista Leiter: Krista.Leiter@hc.msu.edu

Ali G. Hamedani, MD, MHS (2019-2022)
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, PA 19107
Ali.Hamedani@pennmedicine.upenn.edu
Download Dr. Hamedani’s bio here.

Emily Hill, MD (2018-2021)
Baylor College of Medicine
7200 Cambridge, 9A
Houston, TX 77030
emily.j.hill8@gmail.com
Download Dr. Hill’s bio here.

Lan Luo, MD, MS (2020-2023)
Beth Israel Deaconess Medical Center/
Harvard Medical School
Department of Neurology
330 Brookline Ave., KS220
Boston, MA 02215
(617) 667-1337 Fax: (617) 975-5454
lluo2@bidmc.harvard.edu
Download Dr. Luo’s bio here.

Michael McDermott, PhD
University of Rochester
Department of Biostatistics
601 Elmwood Avenue Box 630
Rochester, NY 14642
(585)275-6685 Fax: (585)273-1031
mikem@bst.rochester.edu
Download Dr. McDermott’s bio here.

Delaram Safarpour, MD, MSCE (2019-2022)
Assistant Professor of Neurology
Co-Director of DBS Program
OHSU Parkinson Center & Movement Disorders Program
Portland, Oregon 97239
safarpou@ohsu.edu
Download Dr. Safarpour’s bio here.

Allison Willis, MD (2019-2022)
Pennsylvania Hospital
330 S. 9th Street
Philadelphia, PA 19107
(215) 829-6500 Fax: (215) 829-7724
allison.willis@uphs.upenn.edu

Mentored Clinical Research Award

AWARD OVERVIEW

The PSG MCRA is for new investigators in patient-oriented research in Parkinson’s disease and related disorders.

The Mentored Clinical Research Award (MCRA) for new investigators is funded by a grant from the Parkinson’s Foundation (PF) to the Parkinson Study Group (PSG). The PF collaborates with the PSG to encourage the professional and scientific development of young investigators on their path to independence. To this end, this grant supports a new investigator for a one year project in patient oriented research in Parkinson disease (PD) or other parkinsonian disorders. The new investigator works under the mentorship of an experienced investigator. Training should enhance the junior clinical research skills. The research plan should address unmet needs of people living with PD, have the potential for broad application among the PD community, and lead to advances in clinically relevant treatment options.

Call for MCRA applications coming Spring 2022

PSG Executive Committee

The PSG is governed by a Constitution and an elected Executive Committee that is primarily responsible for the direction and oversight of its research projects and activities.

EXECUTIVE COMMITTEE OVERVIEW

The PSG Executive Committee oversees all the PSG study steering committees, the Scientific Review Committee, the Mentoring Committee, the Nominating Committee, the Credentials Committee, the Publications Committee, the Standards Committee, the Study Budget Committee, and the Symposia Committee. The Executive Committee is also responsible for overseeing the PSG working groups (Atypical Parkinsonian Disorders, Cognitive/Psychiatric (Behavior), Biomarkers, Genetics and Environmental Risk, Health/Care Outcomes and Disparities, Other Non-Motor Features of PD, Functional Neurosurgical and Motor Features of PD) that are responsible for developing new PSG projects. PSG members interested in joining a working group may contact the Chair of that group.

Key Documents

Click below to view/download PDF documents:

PSG Bylaws
PSG Policies & Procedures
Conflict of Interest Guidelines

Click here to download the Executive Committee position statement.

Executive Committee Members

MICHAEL SCHWARZCIHLD, MD, PHD, CHAIR (2018-2024)

Dr. Schwarzschild is a Professor of Neurology at Harvard Medical School and Attending Neurologist at Massachusetts General Hospital. After Parkinson's disease fellowship training at MGH he developed a translational research program focusing on the role of purines — adenosine, caffeine and urate — among environmental and genetic influences in animal models and clinical studies of PD. He has developed and led phase 2/3 clinical trials toward disease-modifying therapy for people with Parkinson’s. At MGH he works with Parkinson's patients and their families in a weekly movement disorders clinic.

HUBERT FERNANDEZ, MD, CO-CHAIR (2018-2024)

Hubert H. Fernandez, MD, is Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Chair/Director of the Center for Neurological Restoration at Cleveland Clinic in Cleveland, Ohio. He is the holder of the James and Constance Brown Family Endowed Chair in Movement Disorders. He received both his BS in Biology and MD degree from the Philippines. He completed his internship in Internal Medicine at University of Pennsylvania/Pennsylvania Hospital in Philadelphia, Pennsylvania; his residency in Neurology at Boston University Medical Center in Boston, Massachusetts; and his fellowship in Movement Disorders at Brown University in Rhode Island.

Dr Fernandez is an internationally recognized expert in movement disorders who has been voted one of the Best Doctors in America by his peers. After completing his medical training, he joined the faculty of Brown University School of Medicine as Assistant Professor in the Department of Clinical Neurosciences. In 2003, Dr Fernandez relocated to the University of Florida, where he eventually became Director of the Clinical Research Unit for Neurological and Psychiatric Disorders, Vice Chair of Academic Affairs, and Professor of Neurology prior to joining Cleveland Clinic. An active and productive researcher, he has led or participated in over 150 clinical trials and has published his findings in over 300 articles on Parkinson disease, DBS, behavioral and non-motor features of PD, cervical dystonia, blepharospasm, and other movement disorders. He has written a dozen books and has published 50 book chapters. He is currently the Co-Editor-In-Chief of Parkinsonism and Related Disorders, and has served on the editorial board of Movement Disorders and several other peer-reviewed journals.

Dr Fernandez is a fellow of the American Academy of Neurology and the American Neurological Association. He is currently elected for his second term as the Co-Chair of the Parkinson Study and Secretary of the International Association for Parkinsonism and Related Disorders, He served his third term as Co-Medical Editor of the Movement Disorders Society Website, which received the Standard of Excellence Award twice by the Web Marketing Association during his tenure. He has been a Councilor for the AAN Movement Disorders Section, Sectretary of the MDS Pan-American Section, Executive Committee Member of the Parkinson Study Group and Dystonia Study Group and served as the President of the Florida Society of Neurology and World Neurology Foundation. He was awarded the Most Outstanding Alumnus by his medical school in 2008, and the Presidential Distinguished Service Award by the Movement Disorders Society at the 16th International Congress for Parkinson’s Disease and Movement Disorders in Dublin, Ireland in 2012.

CINDY CASACELI (2021-2024)

Ms Casaceli has directed the Clinical Trials Coordination Center (CTCC) for over 10 years with more than 25 years experience in the operational conduct of an academic research organization. She has overseen the conduct and compliance of clinical trials that have led to the FDA approve of seven compounds. She has served as the Administrative PI for 8+ studies including NIH funded SURE-PD3, Michael J. Fox Nilo-PD and FoxBioNet, and PDGENE with the Parkinson Foundation. She holds a BS in Biochemistry, MBA in Computer/Information Systems & Accounting, and a Leadership Coaching Certficiate.

Allison Willis, MD, MS (2021-2024)

Dr. Willis is an Associate Professor of Neurology and of Epidemiology (with tenure), a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, a Senior Fellow at the Leonard Davis Institute of Health Economics, and a Faculty Scholar at the Center for Pharmacoepidemiology Research Training at the University of Pennsylvania (UPenn) School of Medicine. She is also the Co-Director of the UPenn Resource Center for Minority Aging Research.

Upon completing an adult neurology residency at the Washington University School of Medicine, Dr. Willis pursued a clinical fellowship in movement disorders and a research training program focused on analytical epidemiology, biostatistics, geographical information systems (spatial epidemiology), pharmacoepidemiology, and health outcomes research (culminating in a Master of Science in Clinical Investigation). She uses analytical epidemiology methods to pursue research questions relevant to clinical decision-making and health policy for neuroaging populations through two complementary investigative paths. Her health services research program focuses on the complex ways patient factors (such as race, sex, comorbid disease, and geographical location) affect the interactions older adults with neurological diseases have with the U.S. health care system. Her pharmacoepidemiology research program focuses on the bidirectional relationships between neurological disease and CNS drug effects- such as whether neurological disease predisposes to specific adverse drug reactions and whether CNS-acting drugs influence neurological disease phenotype or progression.

Dr. Willis has been privileged to serve in several roles in the PSG since joining as a fellow, including Co-Chair of the Healthcare Outcomes and Disparities Working Group, Member of the Mentoring Committee, and Member of the Nominating Committee. She has also enjoyed and benefitted from the research, collaboration, and mentoring opportunities made possible through the PSG at every stage of her career to date. As a fellow/ junior faculty member of the PSG, she has benefitted from PD-focused career development sessions at PSG meetings and learned to affectionately call herself a “Parkinsonologist”. Her cross-training and cross membership in the neurology, epidemiology, aging, and health services research communities requires that she communicate her research credibly for use by multiple stakeholders, varied audiences. Through formal and informal speaking opportunities at the PSG, she learned (and continues to learn) how to communicate her research for use by the academic PD community. Throughout Dr. Willis’s career, PSG members have guided and shaped her research ideas into work with the potential to advance our scientific conversations about health outcomes and disparities in Parkinson disease populations. Finally, the PSG has provided her with multiple opportunities to pursue her favorite teaching activity- mentoring, and has led to successful research collaborations, valued personal and professional connections.

Grace S. Bwala, MBBS, MPH (2021-2024)

Massachusetts General Hospital, Boston, Massachusetts.

Grace was initially raised in the United Kingdom and then in Nigeria where she trained as a primary care physician. During her training, her rotations were spread across many fields of medicine where she learned to manage the overall wellbeing of families. She often worked with non-governmental organizations (NGOs) that helped fund healthcare resources as they served patients in the local villages that could not afford to travel or pay for healthcare. To her this was very gratifying as it geared her thoughts towards public health. This interest led her to obtain her master’s degree in public and global health from New York Medical College about 9 years ago. Overall, her diverse interactions with patients of all age groups have taught her the importance of humility, sacrifice, hard work and creativity. This also gave her insight to explore other ways of building her knowledge through research as those were resources not available in her home country.

Grace joined the Movement Disorders team at MGH in 2007 as a research coordinator where she had the opportunity to focus her time and energy on the care of patients with Parkinson’s Disease. She has coordinated a variety of PSG studies which has given her the opportunity to serve and build great relationships with patients, their families, other study coordinators, monitors and other executive committee members. She currently serve as a Senior Clinical Research Coordinator at MGH, the coordinator for the Parkinson’s Foundation Center of Excellence, and also as a visiting primary care physician in my home country aiding patients that do not have access to healthcare. Being involved with the PSG has given me the opportunity to participate in research studies with which she is proud to be associated, and to learn from many mentors and colleagues.

ERIC MACKLIN (2021-2024)

Dr. Macklin is an Assistant in Biostatistics at Massachusetts General Hospital and an Instructor in the Department of Medicine at Harvard Medical School. His research interests focus on neurodegenerative and neurodevelopmental diseases with an emphasis on clinical trial design.

He is an Executive Committee member of the Parkinson Study Group and an academic advisor for the Critical Path for Parkinson's Consortium. He was an organizing member and the lead biostatistician for the Airlie House Clinical Trials Guidelines for ALS research. He is a lead biostatistician for the Healey ALS Center Platform trial, for the phase 3 SURE-PD3 trial in Parkinson disease, and for the Autism Treatment Network. In addition to his work in neurology, he has a long and ongoing interest in evaluation of complementary and alternative medicine, serving as PI or statistician for trials of acupuncture, Tai Chi, and mind-body practices.

JOEL S PERLMUTTER (2020-2023)

Joel S Perlmutter is Head of Movement Disorders and the Elliot Stein Family Professor of Neurology and Professor of Radiology, Neuroscience, Physical Therapy, and Occupational Therapy as well as Director of the American Parkinson Disease Association Advanced Research Center for Parkinson Disease and Director of the Huntington Disease Center of Excellence at Washington University in St. Louis.

Joohi Jimenez-Shahed (2021-2024)

Dr. Jimenez-Shahed is an Associate Professor of Neurology and Medical Director, Movement Disorders Neuromodulation and Brain Circuit Therapeutics. After completing her undergraduate degree at Washington University in St. Louis, Dr. Jimenez-Shahed received her medical degree from Baylor College of Medicine (BCM) and Neurology residency training at Duke University Medical Center. She then completed a fellowship in Movement Disorders at the Parkinson’s Disease Center and Movement Disorders Clinical (PDCMDC) at BCM. Her research interests lie in investigating the intraoperative neurophysiology of patients undergoing deep brain stimulation (DBS) for movement disorders and the application of wearables and digital health technologies to the care of patients with Parkinson’s disease.

Dr. Jimenez-Shahed joined the PSG fresh out of fellowship in recognition of the networking opportunities it afforded as well as the chance to participate in the latest important clinical research in Parkinson’s disease (PD). As her professional interests developed in the arena of neuromodulation, she sought to develop her ideas within the Functional Neurosurgical Working Group (FNSWG).

As Co-Chair and Chair of the FNSWG, along with her co-I Jim McInerney, she established RAD-PD (Registry for the Advancement of Deep Brain Stimulation in Parkinson’s disease). Funded by MJFF, it is the first official study and database established within the FNSWG. Other FNSWG activities under her leadership have included shepherding several projects to publication or presentation at national meetings and formation of a Neuropsychology Focus Group.

Her additional service to PSG has included serving on the Credentials committee and Nominations committee, mentorship of junior members, and faculty participation at the PSG CME program from 2018-2020. Dr. Jimenez-Shahed has had varied roles in clinical trials over her career including: PI for several DBS investigator-initiated studies; Site Principal Investigator in multiple clinical trials across a variety of movement disorders; Site co-I, sub-I or rater for many more clinical trials; Key Advisor and Opinion Leader for Industry-sponsored trials; Development and implementation of a rater training program for an international clinical trial.

As a result of these activities she is not only knowledgeable about clinical trials and research, but also about PSG infrastructure and resources, and the multi-faceted benefits the PSG offers to members.

ANDREW SIDEROWF, MD, MS (2020-2023)

Andrew Siderowf, MD MS is the Hurtig-Stern Professor of Neurology and the Chief of the Movement Disorders Division in the Penn Perelman School of Medicine Department of Neurology. He received his MD from Duke University, completed residency training at the Hospital of the University of Pennsylvania and fellowship training in Movement Disorders and Experimental Therapeutics at the University of Rochester (under Ira Shoulson, MD). His research addresses the organization and conduct of clinical trials, particularly the use of biomarkers as outcome measures

TANYA SIMUNI, MD (2020-2023)

Dr. Simuni graduated with her medical degree from Leningrad Medical School and completed an internship in medicine in Leningrad, Russia. Dr. Simuni joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build and lead a multidisciplinary movement disorders center that is recognized by the Parkinson’s Foundation, Huntington Disease Society of America and Wilson’s Foundation as a Center of Excellence and serves as a training model in the region. She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological management of PD. She serves on a number of Steering Committees for the PD national clinical trials, several committees of the Parkinson Study Group and the Parkinson Foundation. She is the Site PI and serve on the Steering Committee for the largest PD biomarker initiative funded by the MJFF (PPMI study). Dr. Simuni is the site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT) Northwestern Clinical Site (U10). Dr. Simuni is an active member of the American Academy of Neurology, American Neurological Association, the Movement Disorders Society as well as the Parkinson’s Study Group.

Donna Moszkowicz
Jeanne Paiko
Sarah Sperling
Cindy Wan

Scientific Review Committee

The Scientific Review Committee will review all PSG research proposals including retrospective data mining projects and prospective studies, whether observational or interventional. A primary and secondary reviewer will be assigned and the Committee will review and score each proposal. The Committee will also facilitate contacts with the Mentoring Committee as appropriate. Requests for use of PSG repositories (DNA, CSF, blood, urine, video) will also be reviewed by the Scientific Review Committee. The Scientific Review Committee will consist of a chair and approximately ten to fifteen members to serve terms of three years and will rotate off one third of its members every year.

Who Serves on the PSG SRC?

Download a PDF of the member list here. 

Joel Perlmutter, MD, Chair (2020-2023)
Washington University School of Medicine
Department of Neurology
660 South Euclid Box 8111
St Louis, MO 63110
(314) 362-6026     Fax: (314) 362-0168
Email: joel@npg.wustl.edu
Assistant: Enid McIntosh enidmcintosh@wustl.edu

M. Maral Mouradian, MD, Co-Chair (2020-2023)
William Dow Lovett Professor of Neurology
Vice Chancellor for Faculty Development, Rutgers Biomedical and Health Sciences
Director, RWJMS Institute for Neurological Therapeutics
Rutgers – Robert Wood Johnson Medical School
Director, American Parkinson Disease Association Center for Advanced Research
683 Hoes Lane West, Room 180
Piscataway, NJ 08854
(732) 235-4772     (732) 235-4773     Fax: (248) 325-3115
Email: m.mouradian@rutgers.edu
Executive Assistant: Lauren Kelly lk496@rwjms.rutgers.edu

Christopher A. Beck, PhD (2019-2022)
Associate Professor
Department of Biostatistics & Computational Biology
University of Rochester Medical Center
601 Elmwood Avenue, Box 630
Rochester, NY 14642
(585) 275-6781     Fax: (585) 273-1031
Email: christopher_beck@urmc.rochester.edu
Download Dr. Beck’s bio here.

Jia Li, PhD (2019-2022)
Department of Public Health Sciences
Henry Ford Health System
One Ford Place, 3E
Detroit, MI 48168
Email: jli4@hfhs.org
Download Dr. Li’s bio here.

Jennifer G. Goldman, MD, MS (2020-2023)
Section Chief, Parkinson’s Disease and Movement Disorders, Shirley Ryan Abilitylab
Professor, Department of Physical Medicine & Rehabilitation and Neurology, Northwestern University Feinberg School of Medicine
355 E. Erie Street
Chicago, IL 60611
(312) 238-1000     Fax: (312) 238-3695
Email: jennifer.goldman@northwestern.edu

Alberto Espay, MD, MSc (2020-2023)
Professor of Neurology, Director, Gardner Family Center
Research Chair for Parkinson’s Disease and Movement Disorders
University of Cincinnati
260 Stetson St., Suite 2300
Cincinnati, OH 45267-0525
(513) 558-4035     Fax: (513) 558-7015
Email: Alberto.espay@uc.edu
Assistant: Lori Selm lori.selm@uc.edu

Jill L. Ostrem, MD (2020-2023)
Carlin & Ellen Wiegner Endowed Professor of Neurology
Division Chief, UCSF Movement Disorder and Neuromodulation Center
Weill Institute for Neurosciences
University of California San Francisco
1635 Divisadero Street, Suite 520
San Francisco, CA 94143
(415) 514-6966     Fax: (415) 353-9060
Email: Jill.Ostrem@ucsf.edu

Joseph Savitt, PhD (2018-2021)
University of Maryland School of Medicine
Associate Professor of Neurology
110 S. Paca Street, 3rd Floor
Baltimore, Maryland 21201
(410) 328-7809     Fax: (410) 328-0167
Email: JSavitt@som.umaryland.edu
Download Dr. Savitt’s bio here.

Tatiana Foroud, PhD (2020-2023)
Chair, Department of Medical & Molecular Genetics
Department of Medical and Molecular Genetics
Indiana University School of Medicine
410 W. 10th Street | HS 4000
Indianapolis, IN 46202-3002
(317) 274-2240     Fax: (317) 278-1100
Email: tforoud@iu.edu
Assisttant: Linda Robinson robinlir@iu.edu

Marta San Luciano Palenzuela, MD (2018-2021)
University of California, San Francisco
1635 Divisadero Street, Suite 520
San Francisco, CA 94115
(415) 353-2311     Fax: (415) 353-9060
Email: Marta.SanLucianoPalenzuela@ucsf.edu
Download Dr. San Luciano’s bio here.

Gregory Pontone, MD, MHS (2018-2021)
Director, Parkinson’s Neuropsychiatry Clinical Programs
Johns Hopkins University School of Medicine
Morris K. Udall Parkinson’s Disease Research Center
Associate Professor, Departments of Psychiatry and Neurology
(410) 502-0477
Email: gpontone@jhmi.edu
Download Dr. Pontone’s bio here.

BECOMING A MEMBER

PSG membership shall consist of five distinct but not mutually exclusive categories: 1) Credentialed Members, 2) Committee Members, 3) Working Group Members, 4) Coordinator Members, and 5) Associate Members.

  • 1) Credentialed Members are individuals who have completed the PSG credentialing process and have been granted full approval, provisional approval, or study-specific approval.

  • 2) Committee Members are individuals who have been actively serving on the Executive Committee (EC) or a standing committee or have served in previous years.

  • 3) Working Group Members are individuals who have been actively participating in meetings, projects, and ongoing research of a working group.

  • 4) Coordinator Members are individuals who work at a PSG credentialed site and are currently working or have previously worked on a PSG trial

  • 5) Associate Members shall include: 1) consultants who are actively serving on standing, advisory, or monitoring committees, 2) professional staff at a coordination, biostatistical center, and at sites supporting active* PSG studies 3) investigators who received “study-specific” credentialing for active PSG studies, and 4) affiliates (including from foundations, government, and industry)

*Active PSG studies are those, for which 1) the primary manuscript has not yet been published, and 2) 2 years have not passed since the primary study completion date. Upon publication of the primary manuscript a study is then no longer considered “active.”

Voting Members shall include: Categories 1-4 as stated above

Credentialed members with study-specific approval, associate members, and working group members who are not fully credentialed are not eligible to vote.

Each voting member shall have one vote. Votes are not transferable and cannot be cast by proxy in instances when the presence of the voting member is required.

HOW DO YOU BECOME A MEMBER?

  • 1) Credentialed Members – For information on how to become a credentialed member, please refer to our Credentialing tab

  • 2) Committee Members – Committee members are selected or nominated by their peers to serve in these roles

  • 3) Working Group Members – To become a member of a working group please refer to our list of working groups listed on the site (Click Here). Once you decide on a working group to join, email the chair or co-chair directly to request to be added to the group. They will then approve your membership and officially have you added to the roster.

  • 4) Coordinator Members – Coordinators are can become members either by requesting to join via an email to the PSG Administrative Director or by working at a site that is participating in a PSG study

  • 5) Associate Members – Associate members are added to the PSG database via the administrative team. If you would like to inquire about your membership status, please contact Donna Moszkowicz.

 

Publications & Newsletters

Journal Articles, Letters, Book Chapters, Abstracts, Ancillary Studies & PSG Symposium:

Parkinson Study Group Publications and Abstracts (updated August 2020)

PSG Authorship and Publication Policy

publications